EGFR/VEGFR2-IN-9

EGFR/VEGFR2-IN-9 (Compound 9b) is an inhibitor of VEGFR-2 (IC50 = 1.325 μM) and EGFR (IC50 = 1.891 μM) . EGFR/VEGFR2-IN-9 significantly inhibits the proliferation of multiple cancer cell lines, particularly leukemia cells. EGFR/VEGFR2-IN-9 upregulates the expression levels of Bax, caspase-3, and p53, while downregulating the expression of Bcl-2. EGFR/VEGFR2-IN-9 induces apoptosis and arrests the cell cycle in the G1 phase. EGFR/VEGFR2-IN-9 can be used to investigate anti-tumor angiogenesis and multi-drug resistant cancers[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; Caspase; EGFR; MDM-2/p53; VEGFR

Related Pathways

Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

COC(C=C12)=C(OC)C=C1N=CN=C2NC(C=C3)=CC=C3/C(C)=N/NC(NC4=CC=C(Cl)C=C4)=O

Molecular Formula

C25H23ClN6O3

Molecular Weight

490.94

References & Citations

[1]Aref MMA, et al. Design, synthesis, anticancer evaluation, biological screening, and computational study of novel 6,7-dimethoxyquinazoline derivatives as VEGFR-2 inhibitors and apoptotic inducers. Eur J Med Chem. 2026 Jan 5;301:118187.